MOTS-c Guide

MOTS-c, short for mitochondrial open reading frame of the 12S rRNA type-c, is a 16-amino-acid mitochondrial-derived peptide. Unlike most familiar peptides discussed in wellness marketing, MOTS-c is encoded within mitochondrial DNA rather than the nuclear genome. [1][2]

Research interest centers on metabolic stress signaling: skeletal-muscle glucose handling, insulin sensitivity, exercise adaptation, and age-related physical decline. The important limitation is that most efficacy evidence comes from cells and animals, while human data are mostly biomarker or exercise-response studies. [2][3][4][5]

A registered Phase 2a study of investigational native MOTS-c in adults with prediabetes and overweight or obesity was recruiting as of May 23, 2026, but it had no posted results. That means current public evidence cannot yet establish clinical benefit, dose, long-term safety, or an approved indication. [6]

MOTS-c is part of the mitochondrial-derived peptide field, where short open reading frames within mitochondrial DNA can produce signaling peptides. This has shifted part of the mitochondria discussion from energy production alone toward mitochondria-to-nucleus and mitochondria-to-tissue communication. [2][3]

The 2015 Cell Metabolism discovery work reported that MOTS-c altered cellular metabolic pathways, targeted the folate-methionine cycle, increased endogenous AICAR-related signaling, and activated AMPK-linked pathways in experimental systems. These mechanisms are plausible reasons for interest in glucose metabolism, but they do not by themselves prove a human treatment effect. [2]

Later work linked MOTS-c to exercise biology. In Nature Communications, researchers reported that exercise induced endogenous MOTS-c expression in human skeletal muscle and circulation, and that MOTS-c treatment improved physical performance and muscle-homeostasis measures in mice. [3]

Mechanism language online often compresses this into "exercise mimetic." A more careful phrasing is that MOTS-c appears to overlap with some cellular stress and metabolic pathways engaged by exercise in preclinical models; it is not a replacement for exercise, and human outcome data remain limited. [3][4]

Human evidence for native MOTS-c is mainly observational or physiology-focused. One small study measured plasma MOTS-c in lean and obese individuals and found associations with insulin-sensitivity surrogates, especially in lean participants, but it did not administer MOTS-c as a treatment. [5]

Exercise studies have measured endogenous MOTS-c responses. A randomized acute-exercise study reported that circulating mitochondrial-derived peptides were not related to baseline fitness measures, and that acute endurance exercise increased mitochondrial-derived peptide levels in plasma, with MOTS-c showing a trend rather than a definitive treatment signal. [4]

The 2021 Nature Communications study included human exercise sampling and preclinical intervention experiments. Its human component supports MOTS-c as exercise-responsive biology; its treatment-like performance findings were in mice, not in a completed human efficacy trial. [3]

The most relevant current clinical registry entry is NCT07505745, a Phase 2a randomized, double-blind, placebo-controlled trial of investigational native MOTS-c in adults with prediabetes and overweight or obesity. As of May 23, 2026, the record was recruiting and listed estimated completion in 2028, with no posted results. [6]

Common claims include better insulin sensitivity, fat loss, improved exercise capacity, faster recovery, mitochondrial optimization, and anti-aging. The strongest support for those themes is preclinical, especially the original mouse work showing improved metabolic homeostasis and reduced diet-induced obesity and insulin resistance. [2]

For exercise performance, the evidence is also mostly preclinical. Human studies show endogenous MOTS-c biology may be exercise-responsive, but they do not show that administering MOTS-c improves human endurance, strength, or training outcomes. [3][4]

For metabolic disease, the current human case is hypothesis-generating. Biomarker associations and an active Phase 2a trial justify continued research, but they do not justify consumer claims that MOTS-c treats diabetes, obesity, fatty liver disease, fatigue, or aging. [5][6]

There is no FDA-approved prescribing label for MOTS-c. That means there is no FDA-reviewed contraindication list, adverse-reaction table, drug-interaction profile, pregnancy or lactation guidance, route guidance, or long-term monitoring standard for routine clinical use. [7][8]

FDA safety-risk materials state that compounded drugs containing MOTs-C may pose significant immunogenicity risk for certain routes and may have complexities involving peptide-related impurities and API characterization. FDA also states that it has not identified human exposure data for drug products containing MOTs-C by any route. [7]

The May 14, 2026 FDA 503A bulk-substances PDF should be read alongside the safety-risk page. MOTs-C no longer appears in the active Category 2 table in that PDF because the nomination was withdrawn, but the FDA safety-risk page still keeps MOTs-C in the withdrawn-nomination risk table. [7][8]

The practical safety takeaway is conservative: animal tolerability and endogenous-human biology do not establish safety for injected, compounded, or research-market products. Identity, purity, sterility, endotoxin control, concentration accuracy, immune reactions, and long-term metabolic effects remain material uncertainties. [7]

There is no FDA-approved MOTS-c label with consumer storage or handling instructions. Without an approved label, there is no authoritative public standard for storage temperature, beyond-use dating, reconstitution, concentration, route, sterility testing, or impurity thresholds for a finished MOTS-c drug product. [7][8]

Research suppliers may publish handling instructions for laboratory material, but those instructions are not the same thing as validated directions for human administration. A label that says "research use only" should not be interpreted as evidence of clinical safety, legal status, sterility, or correct identity. [7]

This profile therefore does not provide reconstitution instructions, injection technique, storage protocols, cycle plans, or purchase guidance. Handling questions for investigational material belong inside an approved study protocol or properly regulated professional setting.

References below prioritize official FDA materials, ClinicalTrials.gov records, PubChem/NLM identity data, and peer-reviewed primary or human physiology literature. Regulatory and trial-record sources were checked on May 23, 2026.